FDA
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Raised to $58 at BofA Securities
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Scholar Rock (SRRK)
-
-
-
-
-
-
-
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
FDA rejects Scholar Rock's apitegromab application due to facility issues
-
-
-
-
-
-
-
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
-
-
-
-
-
-
-
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
-
-
-
-
-
-
-
Factbox-Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
-
326,408 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

